ARTICLE | Company News
Priority Review for Novartis' LCZ696
February 14, 2015 2:03 AM UTC
FDA granted Priority Review to LCZ696 from Novartis AG (NYSE:NVS; SIX:NOVN) to treat heart failure with reduced ejection fraction. Novartis said the PDUFA date will be in August, but did not give a specific date.
LCZ696, a crystalline complex of valsartan and sacubitril in an equimolar ratio, has Fast Track designation from FDA. ...